Resistance to antibody neutralization in HIV-2 infection occurs in late stage disease and is associated with X4 tropism

No abstract is available for this paper.

• Publication year

  2012

• Venue

  AIDS (London)

• Publication date

  2012-11-28

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1097/QAD.0b013e328359a89dPMID 23151495
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Molecular determinants of HIV-2 R5-X4 tropism in the V3 loop: development of a new genotypic tool.

  2012cited by this paper
• Foxp3(+) follicular regulatory T cells control the germinal centre response

  2012cited by this paper
• Baseline Susceptibility of Primary HIV-2 to Entry Inhibitors

  2012cited by this paper
• Foxp3+ follicular regulatory T cells control T follicular helper cells and the germinal center response

  2011cited by this paper
• Broad and Potent Neutralizing Antibody Responses Elicited in Natural HIV-2 Infection

  2011cited by this paper
• Regulation of the Germinal Center Reaction by Foxp3+ Follicular Regulatory T Cells

  2011cited by this paper
• Potent Autologous and Heterologous Neutralizing Antibody Responses Occur in HIV-2 Infection across a Broad Range of Infection Outcomes

  2011cited by this paper
• Potent Intratype Neutralizing Activity Distinguishes Human Immunodeficiency Virus Type 2 (HIV-2) from HIV-1

  2011cited by this paper
• Memory and naive-like regulatory CD4+ T cells expand during HIV-2 infection in direct association with CD4+ T-cell depletion irrespectively of viremia

  2011cited by this paper
• Temporal analysis of HIV envelope sequence evolution and antibody escape in a subtype A-infected individual with a broad neutralizing antibody response.

  2010cited by this paper
• High prevalence of neutralizing activity against multiple unrelated human immunodeficiency virus type 1 (HIV-1) subtype B variants in sera from HIV-1 subtype B-infected individuals: evidence for subtype-specific rather than strain-specific neutralizing activity.

  2010cited by this paper
• The role of antibodies in HIV vaccines.

  2010cited by this paper
• A series of PDB related databases for everyday needs

  2010cited by this paper
• Potent and Broadly Reactive HIV-2 Neutralizing Antibodies Elicited by a Vaccinia Virus Vector Prime-C2V3C3 Polypeptide Boost Immunization Strategy

  2010cited by this paper
• Prevalence of cross-reactive HIV-1-neutralizing activity in HIV-1-infected patients with rapid or slow disease progression

  2009cited by this paper
• Breadth of Human Immunodeficiency Virus-Specific Neutralizing Activity in Sera: Clustering Analysis and Association with Clinical Variables

  2009cited by this paper
• Measuring HIV neutralization in a luciferase reporter gene assay.

  2009cited by this paper
• Major Depletion of Plasmacytoid Dendritic Cells in HIV-2 Infection, an Attenuated Form of HIV Disease

  2009cited by this paper
• The immune response during acute HIV-1 infection: clues for vaccine development

  2009cited by this paper
• Envelope-specific antibody response in HIV-2 infection: C2V3C3-specific IgG response is associated with disease progression

  2008cited by this paper
• Autologous Neutralizing Humoral Immunity and Evolution of the Viral Envelope in the Course of Subtype B Human Immunodeficiency Virus Type 1 Infection

  2008cited by this paper
• The SWISS-MODEL Repository and associated resources

  2008cited by this paper
• The role of the humoral immune response in the molecular evolution of the envelope C2, V3 and C3 regions in chronically HIV-2 infected patients

  2008cited by this paper
• Net Positive Charge of HIV-1 CRF01_AE V3 Sequence Regulates Viral Sensitivity to Humoral Immunity

  2008cited by this paper
• Tenets of protection from progression to AIDS: lessons from the immune responses to HIV-2 infection

  2008cited by this paper
• Comparison of viro-immunological marker changes between HIV-1 and HIV-2-infected patients in France

  2008cited by this paper
• Comparison of Heterologous Neutralizing Antibody Responses of Human Immunodeficiency Virus Type 1 (HIV-1)- and HIV-2-Infected Senegalese Patients: Distinct Patterns of Breadth and Magnitude Distinguish HIV-1 and HIV-2 Infections

  2007cited by this paper
• Monocyte‐mediated T cell suppression by HIV‐2 envelope proteins

  2007cited by this paper
• In vitro replication capacity of HIV-2 variants from long-term aviremic individuals.

  2006cited by this paper
• The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling

  2006cited by this paper
• Increased Frequency of Circulating CCR5+ CD4+ T Cells in Human Immunodeficiency Virus Type 2 Infection

  2006cited by this paper
• Maintenance of HIV-Specific CD4+ T Cell Help Distinguishes HIV-2 from HIV-1 Infection1

  2006cited by this paper
• CCR5, GPR15, and CXCR6 Are Major Coreceptors of Human Immunodeficiency Virus Type 2 Variants Isolated from Individuals with and without Plasma Viremia

  2005cited by this paper
• Cryptic Nature of a Conserved, CD4-Inducible V3 Loop Neutralization Epitope in the Native Envelope Glycoprotein Oligomer of CCR5-Restricted, but Not CXCR4-Using, Primary Human Immunodeficiency Virus Type 1 Strains

  2005cited by this paper
• Structure of an unliganded simian immunodeficiency virus gp120 core

  2005cited by this paper
• Cutting Edge: Direct Suppression of B Cells by CD4+CD25+ Regulatory T Cells1

  2005cited by this paper
• Evolution of human immunodeficiency virus type 2 coreceptor usage, autologous neutralization, envelope sequence and glycosylation.

  2005cited by this paper
• Structural rationale for the broad neutralization of HIV-1 by human monoclonal antibody 447-52D.

  2004cited by this paper
• Rapid evolution of the neutralizing antibody response to HIV type 1 infection

  2003cited by this paper
• Alternative conformations of HIV-1 V3 loops mimic beta hairpins in chemokines, suggesting a mechanism for coreceptor selectivity.

  2003cited by this paper
• Human Immunodeficiency Virus Type 1 Primary Isolate Neutralization Resistance Is Associated with the Syncytium-Inducing Phenotype and Lower CD4 Cell Counts in Subtype CRF01_AE-Infected Patients

  2003cited by this paper
• Antibody neutralization and escape by HIV-1

  2003cited by this paper
• CD4+ T-cell depletion in HIV infection: Are we closer to understanding the cause?

  2002cited by this paper
• Marked immunosuppressive effects of the HIV-2 envelope protein in spite of the lower HIV-2 pathogenicity

  2000cited by this paper
• Quantitation of Human Immunodeficiency Virus Type 2 DNA in Peripheral Blood Mononuclear Cells by Using a Quantitative-Competitive PCR Assay

  1999cited by this paper
• Low peripheral blood viral HIV-2 RNA in individuals with high CD4 percentage differentiates HIV-2 from HIV-1 infection.

  1998cited by this paper
• Virological and Molecular Demonstration of Human Immunodeficiency Virus Type 2 Vertical Transmission

  1998cited by this paper
• Evidence that Antibody-Mediated Neutralization of Human Immunodeficiency Virus Type 1 by Sera from Infected Individuals Is Independent of Coreceptor Usage

  1998cited by this paper
• Location, exposure, and conservation of neutralizing and nonneutralizing epitopes on human immunodeficiency virus type 2 SU glycoprotein

  1996cited by this paper
• Change in tropism upon immune escape by human immunodeficiency virus

  1995cited by this paper
• Immune escape and tropism of HIV.

  1995cited by this paper
• Neutralizing monoclonal antibodies against human immunodeficiency virus type 2 gp120

  1995cited by this paper
• The Swiss-3DImage collection and PDB-Browser on the World-Wide Web.

  1995cited by this paper
• Two neutralizing domains in the V3 region in the envelope glycoprotein gp125 of HIV type 2.

  1994cited by this paper
• Reduced rate of disease development after HIV-2 infection as compared to HIV-1.

  1994cited by this paper
• Autologous neutralizing antibodies prevail in HIV-2 but not in HIV-1 infection.

  1993cited by this paper
• Cross-neutralization of human immunodeficiency virus type 1 and 2 and simian immunodeficiency virus isolates

  1992cited by this paper
• Hyperimmune antisera against synthetic peptides representing the glycoprotein of human immunodeficiency virus type 2 can mediate neutralization and antibody-dependent cytotoxic activity.

  1991cited by this paper
• A capture enzyme immunoassay for detection of HIV-2/SIV antigen.

  1991cited by this paper
• Envelope cross-reactivity between human immunodeficiency virus types 1 and 2 detected by different serological methods: correlation between cross-neutralization and reactivity against the main neutralizing site

  1990cited by this paper
• Dictionary of protein secondary structure: Pattern recognition of hydrogen‐bonded and geometrical features

  1983cited by this paper

• Tracking coreceptor switch of the transmitted/founder HIV-1 identifies co-evolution of HIV-1 antigenicity, coreceptor usage and CD4 subset targeting

  2023cites this paper
• Tracking coreceptor switch of the transmitted/founder HIV-1 identifies co-evolution of HIV-1 antigenicity, coreceptor usage and CD4 subset targeting: the RV217 acute infection cohort study

  2023cites this paper
• An HIV-1/HIV-2 Chimeric Envelope Glycoprotein Generates Binding and Neutralising Antibodies against HIV-1 and HIV-2 Isolates

  2023cites this paper
• Long-Term and Low-Level Envelope C2V3 Stimulation by Highly Diverse Virus Isolates Leads to Frequent Development of Broad and Elite Antibody Neutralization in HIV-1-Infected Individuals

  2022cites this paper
• High Instantaneous Inhibitory Potential of Bictegravir and the New Spiro-β-Lactam BSS-730A for HIV-2 Isolates from RAL-Naïve and RAL-Failing Patients

  2022cites this paper
• Intra-Patient Evolution of HIV-2 Molecular Properties

  2022cites this paper
• HIV-2 Neutralization Sensitivity in Relation to Co-Receptor Entry Pathways and Env Motifs

  2022influential citation
• Computational Modulation of the V3 Region of Glycoprotein gp125 of HIV-2

  2021cites this paper
• Spiro-β-lactam BSS-730A Displays Potent Activity against HIV and Plasmodium.

  2021cites this paper
• Computational approaches for improving treatment and prevention of viral infections

  2019cites this paper
• HIV Co-Receptor Usage, Broadly Neutralising Antibodies, and Treatment

  2019cites this paper
• HIV-1 co-receptor usage and variable loop contact impacts V3 loop bnAb susceptibility

  2019cites this paper
• Characterization of HIV-2 susceptibility to protease and entry inhibitors and identification of envelope determinants of coreceptor usage, cell tropism and antibody neutralization

  2018cites this paper
• Potency of HIV-2-specific antibodies increase in direct association with loss of memory B cells

  2017cites this paper
• Geno2pheno (coreceptor-hiv2): a new diagnostic tool for the genotypic determination of HIV-2 coreceptor usage

  2016cites this paper
• Humoral Immune Pressure Selects for HIV-1 CXC-chemokine Receptor 4-using Variants

  2016cites this paper
• HIV Interaction With Human Host: HIV-2 As a Model of a Less Virulent Infection.

  2016cites this paper
• A genotypic method for determining HIV-2 coreceptor usage enables epidemiological studies and clinical decision support

  2016cites this paper
• How does the humoral response to HIV-2 infection differ from HIV-1 and can this explain the distinct natural history of infection with these two human retroviruses?

  2015cites this paper
• Antiretroviral therapy and drug resistance in human immunodeficiency virus type 2 infection.

  2014cites this paper
• HIV-2 Envelope: Structure, Diversity, and Evolution

  2014cites this paper
• Cross-Neutralizing Antibody Profile of Chinese HIV-1-Infected Individuals and the Viral Envelope Features From Elite Neutralizers

  2014cites this paper
• Thymic HIV-2 Infection Uncovers Posttranscriptional Control of Viral Replication in Human Thymocytes

  2014cites this paper
• HIV-2 susceptibility to entry inhibitors.

  2013cites this paper
• Evolution of the human immunodeficiency virus type 2 envelope in the first years of infection is associated with the dynamics of the neutralizing antibody response

  2013influential citation
• Analysis of antibody neutralization specificities in human immunodeficiency virus type 2 infection

  2013influential citation